Surrozen, Inc. (SRZN): Total Liabilities
$286.49M
As of 2025-12-31
$334.27M
As of 2026-06-30
+177.3%
3-year compound annual growth
+81.0%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $286.49M | +310.2% | 2026-03-23, Balance as of period end |
| 2024-12-31 | $69.85M | +757.5% | 2026-03-23, Balance as of period end |
| 2023-12-31 | $8.14M | -39.4% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $13.43M | -51.1% | 2024-04-10, Balance as of period end |
| 2021-12-31 | $27.47M | +86.0% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $14.77M | n/a | 2022-03-28, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Surrozen, Inc. (SRZN) | 2025-12-31 | $286.49M | +310.2% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $343.43M | +10.8% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $8.71M | +16.8% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $38.99M | +82.0% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | $55.68M | +5.4% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $221.87M | +53.7% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $2.95M | -10.5% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $34.99M | -64.7% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $64.95M | +69.7% |
Compare SRZN, CRSP, DYAI, CGON side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗